Moderna Inc. (NASDAQ:MRNA) does about 21.86M shares in volume on a normal day but saw 6330736 shares change hands in Friday trading. The company now has a market cap of 26.84B USD and an enterprise value of about $24.29B. Its current market price is $67.49, marking a decrease of -0.79% compared to the previous close of $68.03. The 52 week high reached by this stock is $95.21 whilst the lowest price level in 52 weeks is $13.53. The script in recent trading has seen the stock touch a high of $68.95 and a low of $67.15.

Moderna Inc. (MRNA) has a 20-day trading average at $70.19 and the current price is -29.11% off the 52-week high compared with 398.82% distance from its 52-week low. The 50-day simple moving average of the closing price is $70.67 and its 200-day simple moving average is $42.73. If we look at the stock’s price movements over the week, volatility stands at 5.79%, which decreases to 5.17% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 47.37 to suggest the stock is neutral.

The consensus objective for the share price is $91.90, suggesting that the stock has a potential upside of 26.56% over the period.

FactSet Research has provided data showing that 15 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 12 analysts have rated it as a buy and 3 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on July 23, 2020 when SVB Leerink initiated the stock to “Mkt Perform” and issued a price target of. JP Morgan downgraded the stock to “Neutral” from Overweight on July 20, 2020 at a price target of $89. Jefferies initiated its price target at $90.

The current price level is -4.30%, -4.43%, and 58.87% away from its SMA20, SMA50, and SMA200 respectively, with the MRNA price moving above the 50-day SMA on August 28. Moderna Inc. (MRNA) stock is up 1.57% over the week and -13.06% over the past month. Its price is 245.04% year-to-date and 344.60% over the past year.

The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of -$0.31 above consensus estimates by $0.04. The company’s next earnings report is expected on 11/04/2020, with forecasts estimating quarterly EPS at -$0.44 and -$1.5 for whole year. MRNA’s earnings per share are forecast to grow by 3.20% this year and 254.00% over next year. Expected sales for next quarter are $154.06 million, which analysts say will come at $327.3 million for the current fiscal year and next year at $4.69 billion. In addition, estimates put the company’s current quarterly revenue at an average of $75.43 million.

Its 12-month price target is $92.00. To reach the target analysts have set, the stock logically needs to grow 26.56 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $58.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $134.00.

Outstanding shares total 380.53M with insiders holding 23.94% of the shares and institutional holders owning 53.53% of the company’s common stock. The company has a return on investment of -44.90% and return on equity of -27.80%. The forward price to earnings ratio is 29.15. Price to book ratio is 8.72 and price to sales ratio is 253.72.

According to a U.S. Securities and Exchange Commission filing, Fidelity Growth Company Fund has added its position in Moderna Inc. (MRNA) to 15,871,807 shares, mirroring a recent increase by 8.35%. Fidelity Growth Company Fund added 1.22 million shares of Moderna Inc. common stock bringing its total worth to about $1.18 billion at the end of recent close, SEC documents show. Fidelity Growth Company Fund isn’t the only investment manager who changed stakes and is followed by Vanguard Total Stock Market Index, which sold off 30904.0 shares to end up with 7,735,189 shares worth $573.18 million. Vanguard Mid Cap Index Fund cut their holdings by -0.73% in the company over the course of the most recent quarter. It now holds a 1.72% position in Moderna Inc. thanks to 6.68 million shares amounting to $495.06 million.